Preclinical studies identifying carboplatin as a viable cisplatin alternative
- PMID: 3910219
- DOI: 10.1016/0305-7372(85)90015-5
Preclinical studies identifying carboplatin as a viable cisplatin alternative
Abstract
The claims of eight cisplatin analogues as viable alternatives to the parent drug are discussed in terms of their toxicities, antitumour properties and potential biochemical selectivities. It is concluded that, of the eight, diammine (1,1-cyclobutane dicarboxylato)platinum(II) (carboplatin, CBDCA, JM8) had the features most desirable to merit its clinical evaluation.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources